Curtis Hagedorn, MD
Ophthalmology · Denver, CONPI 1508863382
Payments from drug & device makers
Across 306 payments — averaging $5022.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$969K
- Amgen$198K
- Regeneron$184K
- Boehringer Ingelheim$127K
- Janssen Research & Development, LLC$37K
- US Retina LLC$15K
- plus $7K from 13 others
Across 9 payments — averaging $1362.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$10K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 69 | $968,894 |
| Amgen | 7 | $197,651 |
| Regeneron | 87 | $183,620 |
| Boehringer Ingelheim | 20 | $126,757 |
| Janssen Research & Development, LLC | 12 | $37,273 |
| US Retina LLC | 8 | $15,430 |
| Boehringer Ingelheim International GmbH | 41 | $3,738 |
| AbbVie(2 entities) | 9 | $937 |
| Genentech, Inc. | 5 | $909 |
| Astellas Pharma US Inc | 14 | $453 |
| Genentech USA, Inc. | 17 | $411 |
| Regeneron Healthcare Solutions, Inc. | 3 | $285 |
| Astellas Pharma Global Development | 1 | $164 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Novartis | 4 | $72 |
| Alimera Sciences, Inc. | 4 | $71 |
| Eyepoint US, Inc. | 1 | $55 |
| Biogen | 2 | $34 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
How this compares
$1,536,843 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Denver
- Michael JansenDenver$1.8M
- Cristos IfantidesDenver$1.4M
- Mark DaceyDenver$798K
- Peter HovlandDenver$568K
- Kingsley OkaforDenver$317K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael SolomonDenver$12K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.